News Story: Full Text
Sponsored By
Tocagen Clinical Trial
Please Click On The Above Banner For More Details
Braintumor Website


NeoTherapeutics` Subsidiary, NeoOncoRx, to Acquire Phase 2 Anti-Cancer Drug EO9 From NDDO Research Foundation (PR Newswire)NeoTherapeutics, Inc. announced today that its newly formed anti-cancer subsidiary, NeoOncoRx, Inc., has signed a letter of intent to acquire anti- cancer compound E09 and 79 analogs from Netherlands-based NDDO Research Foundation.- Jan 04 3:48 PM ET

IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source:

(Everything below this line is from!)

Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557